Results 131 to 140 of about 13,195 (282)

Perspectives of autophagy-tethering compounds (ATTECs) in drug discovery

Medicine Plus
Degrader technologies provide unprecedented strategies to tackle diseases caused by pathogenic proteins that are difficult to target by the traditional inhibitor approach.
Yu Ding, Dong Xing, Yiyan Fei, Shouqing Luo, Boxun Lu   +4 more
doaj   +1 more source

Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Interspecies cross‐reactive protein therapeutics that target conserved epitopes across species are critical for translational research. The present study showcases the engineering of an affibody molecule, originally discovered for binding to human death receptor 5 (hDR5) with 94 nM affinity, to simultaneously acquire cross‐reactivity to murine
Tse‐Han Kuo, Nagamani Vunnam, Jonathan N. Sachs, Benjamin J. Hackel   +3 more
wiley   +1 more source

Interpretable PROTAC Degradation Prediction With Structure‐Informed Deep Ternary Attention Framework

Advanced Science
Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional ligands bridging Proteins‐Of‐Interest (POIs) and E3 ligases for ubiquitin‐proteasome degradation, promising to target the ‘undruggable’.
Zhenglu Chen, Chunbin Gu, Shuoyan Tan, Xiaorui Wang, Yuquan Li, Mutian He, Ruiqiang Lu, Shijia Sun, Chang‐Yu Hsieh, Xiaojun Yao, Huanxiang Liu, Pheng‐Ann Heng   +11 more
doaj   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Synthesis and Biological Evaluation of Well‐Defined M6P(n)‐Modified Glycopeptides for Targeted Protein Degradation

Chemistry – A European Journal, EarlyView.
A synthetic methodology has been developed to prepare multifunctional M6P and M6Pn ligands of different valency. The glycopeptides were conjugated to cetuximab and then examined to mediate cellular uptake of fluorescently labeled EGFRvIII. Only cetuximab modified by glycopeptides having 3 or 6 M6P or M6Pn residues demonstrated greater uptake.
Patrycja Lenartowicz, Jan‐Willem H. Langenbach, Nataliia Voloshyna, David Aidukas, Arwin J. Brouwer, John A. W. Kruijtzer, Geert‐Jan Boons   +6 more
wiley   +1 more source

PROTAC-based protein degradation: a window of opportunity for melanoma therapy

Journal of Biomedical Science
The key small molecule-based modalities for inducing targeted protein degradation have seen explosive growth over the past decade. They include heterobifunctional degraders such as PROteolysis TArgeting Chimeras (PROTACs): molecules working as protein ...
Giulia Gentile, Simona D’Aguanno, Marta Di Martile, Adele Petricca, Elisabetta Valentini, Stefano Scalera, Donatella Del Bufalo   +6 more
doaj   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

Detection of the GH Analogue Redalsomatropin Alfa in Sports Drug Testing: Immunological Approaches and LC‐HRMS/MS

Drug Testing and Analysis, EarlyView.
After evaluating the compatibility of the GH analogue redalsomatropin alfa with approved doping control immunoassays for rhGH, it was implemented into the existing detection method for somatrogon employing affinity purification with GHR‐Fc‐conjugated magnetic beads, tryptic digestion, and LC‐HRMS/MS to allow for a specific and sensitive detection ...
Katja Walpurgis, Andreas Thomas, Jasmin Thelen, Bettina Majer, Maneera Al‐Jaber, Wadha Abushareeda, Mario Thevis   +6 more
wiley   +1 more source